Infinity Pharmaceuticals, Inc.   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Cambridge MA United States (1995)

Organization Overview

First Clinical Trial
2005
NCT00113204
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Infinity Pharmaceutical, Inc. | Infinity Pharmaceuticals, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 1)

Adrenocortical Carcinoma (Phase 1)

Breast Neoplasms (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Renal Cell (Phase 2)

Carcinoma, Squamous Cell (Phase 1)

Carcinoma, Transitional Cell (Phase 2)

Chondrosarcoma (Phase 2)

Gastrointestinal Stromal Tumors (Phase 3)

Head and Neck Neoplasms (Phase 1)

Leukemia (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)

Leukemia, Lymphoid (Phase 2)

Liposarcoma (Phase 2)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 1)

Lymphoma, Non-Hodgkin (Phase 1)

Lymphoma, T-Cell (Phase 1)

Melanoma (Phase 2)

Mesothelioma (Phase 1)

Multiple Myeloma (Phase 1)

Neoplasms (Phase 1)

Neoplasms, Plasma Cell (Phase 1)

Neoplasms, Squamous Cell (Phase 1)

Pancreatic Neoplasms (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Primary Myelofibrosis (Phase 2)

Prostatic Neoplasms (Phase 2)

Sarcoma (Phase 1)

Triple Negative Breast Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 27
  • # of Trial APIs: 21